Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 

Slides:



Advertisements
Similar presentations
Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.
Advertisements

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.
Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.
Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos 
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies  Marcelo C. Pasquini,
A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors  Navneet S. Majhail, Hillard M. Lazarus, Linda.
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Biology of Blood and Marrow Transplantation
Bone Marrow Transplantation for Diamond-Blackfan Anemia
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia  Karen K. Ballen, Ann E. Woolfrey, Xiaochun.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.
Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia  Collin C. Barker, Manza-A. Agovi, Brent Logan,
Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Marcel P. Devetten,
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
J. J. Nietfeld, Marcelo C. Pasquini, Brent R
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia  Jennifer.
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation  Philippe Armand, Haesook T. Kim, Daniel.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic.
Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin.
Biology of Blood and Marrow Transplantation
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation  Ajay K. Nooka,
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
Jeffrey Schriber, Manza-A. Agovi, Vincent Ho, Karen K
Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival  Victor H. Jimenez-Zepeda,
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S
Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia  William A. Wood,
Blood and Marrow Transplant Handbook
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R
Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma  Tanya M. Wildes, Kristan M. Augustin, Diane.
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.
Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia 
Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗  Theresa Hahn, Philip L. McCarthy,
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Luciano J. Costa, Jia-Xing Huang, Parameswaran.
Presentation transcript:

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation  Yi-Bin Chen, Andrew A. Lane, Brent R. Logan, Xiaochun Zhu, Görgün Akpek, Mahmoud D. Aljurf, Andrew S. Artz, Christopher N. Bredeson, Kenneth R. Cooke, Vincent T. Ho, Hillard M. Lazarus, Richard F. Olsson, Wael Saber, Philip L. McCarthy, Marcelo C. Pasquini  Biology of Blood and Marrow Transplantation  Volume 21, Issue 6, Pages 1046-1053 (June 2015) DOI: 10.1016/j.bbmt.2015.02.005 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Adjusted probability of overall survival after autologous hematopoietic cell transplantation for (A) Hodgkin lymphoma, (B) follicular lymphoma, (C) diffuse large B cell lymphoma, and (D) mantle cell lymphoma according to conditioning regimen. Biology of Blood and Marrow Transplantation 2015 21, 1046-1053DOI: (10.1016/j.bbmt.2015.02.005) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.